The Spring 2026 Prime Therapeutics Report delivers a forward-looking view of specialty and rare disease management—highlighting breakthrough approvals, expanding pipelines and the payer strategies needed to manage rising complexity and cost.
This issue examines how cell and gene therapies are moving beyond oncology, how rare disease treatment landscapes are rapidly evolving, and what managed care leaders can do now to prepare for what’s ahead.

Inside this issue:

• Cell and gene therapy: Expanding pipeline, multimillion-dollar therapies and emerging payment models
• Hereditary angioedema: New oral, RNA-targeted and monoclonal antibody options reshaping prophylaxis and acute care
• Myasthenia gravis: Targeted therapies, payer utilization trends and cost management strategies
• Spinal muscular atrophy: New gene therapy approvals, dosing innovations and transition-of-care challenges
• Biosimilars: Key approvals, launches and competitive dynamics across oncology and beyond
• Pipeline outlook: High-impact approvals and FDA decisions expected in 2026

Whether you’re a managed care executive, clinician or pharmacy leader, this report offers practical insights to help you evaluate high-cost therapies, plan for pipeline disruption and design smarter coverage and payment strategies—while keeping patient access at the center of care.

Read the Full Report

Subscribe for Future Issues